language_icon
EN
HI

Dr Lal Pathlabs. Share price

LALPATHLAB

1408.9

22.00 (-1.54%)
NSE
BSE
Last updated on 24 Apr, 2026 | 15:31 IST
Today's High

1435.50

Today's Low

1399.90

52 Week Low

1272.60

52 Week High

1770.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Dr Lal Pathlabs Chart

Dr Lal Pathlabs. Share Key Metrics

Volume
3.25 L
Market Cap
23606.83 CR
LTQ@LTP
13@1408.90
ATP
1411.96
Var Margin
13.83 %
Circuit Range
1144.8-1717
Delivery %
63.34 %
Value
45.83 CR
ASM/GSM
No
Market Lot
1

Summary

24 Apr, 2026 | 15:31 को, Dr Lal Pathlabs. का शेयर प्राइस आज ₹1408.9 पर है, जो दिन के लिए 22.00% की -1.54 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹1399.90 और ₹1435.50 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹1272.60 से ₹1770.00 तक रही है। ट्रेडिंग गतिविधि के मामले में, Dr Lal Pathlabs. ने 324606 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹167555020 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹141196 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 13,140890 रही। यह स्टॉक ₹1144.8-1717 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹45.83 CR है। दिन के लिए डिलीवरी परसेंटेज 63.34% रही। इसके अतिरिक्त, Dr Lal Pathlabs. वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Dr Lal Pathlabs. Fundamentals

View More
P/E Ratio

45.39

P/B Ratio

9.36

Div. Yield

0.84

Sector P/E

53.91

Sector P/B

-16.17

Sec. Div. Yield

2.23

Dr Lal Pathlabs. Resistance and Support

Pivot 1440.97

Resistance

First Resistance

1458.94

Second Resistance

1486.97

Third Resistance

1504.94

Support

First Support

1412.94

Second Support

1394.97

Third Support

1366.94

Dr Lal Pathlabs. Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

53.21%

Mutual Fund

18.62%

Insurance

2.33%

Foreign Institutional Investors

17.18%

Domestic Institutional Investors

0.3%

Retail

8.35%

Others

0.01%

Total Promoters
MAR '26
53.21%

Dr Lal Pathlabs. Corporate Actions

DateAgenda
2026-04-30Audited Results
2026-01-30Quarterly Results & Interim Dividend

Dr Lal Pathlabs. News

Dr. Lal Path Labs Ltd.

DR. LAL PATH LABS LTD. board to meet on April 30, 2026, to consider Q4 and FY26 financial results and recommend a final dividend. This meeting is a continuation of the earlier intimation dated March 27, 2026.
Apr 23 2026 18:04:00

Dr. Lal Path Labs Ltd.

DR. LAL PATH LABS LTD. board to meet on April 30, 2026, to consider Q4 and FY26 financial results and recommend a final dividend. This meeting is a continuation of the earlier intimation dated March 27, 2026.
Apr 23 2026 18:04:00

Dr. Lal Path Labs Ltd.

Dr. Lal PathLabs' Board will convene on April 30, 2026, to approve audited financial results for the quarter and full financial year ended March 31, 2026. The meeting will also consider and recommend a final dividend for FY2025-26.
Apr 23 2026 18:04:00

Dr. Lal PathLabs Ltd - 539524 - Corporate Action-Board to consider Dividend

Dr. Lal Path Labs board will consider and recommend a final dividend for FY2025-26 at its meeting on April 30, 2026. This will be alongside the approval of audited financial results for Q4 and FY26.
Apr 23 2026 18:04:00

Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs released its shareholding pattern for Q4 FY26. Promoter and promoter group hold 53.21% of total shares, while public shareholding is 46.44%. Mutual Funds hold 18.62% and FPIs hold 16.95%.
Apr 20 2026 18:04:00
Read More

About Dr Lal Pathlabs. AboutThe

NSE : 11654  
BSE : 539524  
ISIN : INE600L01024  

Late Dr. Major S.K. Lal commenced the business of providing pathology services and maintaining a blood bank in the year 1949 through sole proprietorship M/s Central Clinical Laboratory and M/s Blood Bank Transfusion Centre. The business of diagnostic and related healthcare tests and services now continues to be provided by the Company. Subsequently Late Dr. Major S.K. Lal and (Hony.) Brig. Dr. Arvind Lal entered into a partnership under the name 'Central Clinical Laboratory' pursuant to a partnership deed dated March 21 1975 with the partnership deemed to have commenced from December 1 1974. The partnership firm was formed to provide pathology services under the name ?Central Clinical Laboratory? and to maintain a blood bank for the supply of blood to patients and hospitals under the name ?Blood Transfusion Centre? both to be undertaken at the Registered Office of the Company. On December 5 1977 following the demise of Late Dr. Major S.K. Lal Late Ms. Vimla Lal wife of Late Dr. Major S.K. Lal was inducted into the partnership with (Hony.) Brig. Dr. Arvind Lal. Following Late Ms. Vimla Lal?s demise Dr. Vandana Lal was inducted into the partnership by a deed of partnership dated January 2 2007. Accordingly as on date Central Clinical Laboratory is a 50:50 partnership between Dr. Vandana Lal and (Hony.) Brig. Dr. Arvind Lal. the Company was incorporated as ?Dr. Lal PathLabs Private Limited? a private limited company under the Companies Act 1956 with a certificate of incorporation granted by the RoC on February 14 1995 at Delhi. The business of the partnership firm Central Clinical Laboratory is now undertaken by the Company while Central Clinical Laboratory does not undertake any business operations. the Company was converted into a public company pursuant to a special resolution of the shareholders of the Company at an EGM held on August 7 2015. Consequently the name of the Company was changed to ?Dr. Lal PathLabs Limited? and a fresh certificate of incorporation pursuant to the change of name was granted by the RoC on August 19 2015.Awards and accreditations :2001-Received the ISO 9001:2008 certification for the quality management system for performance of routine and advanced diagnostic pathology testing services including in clinical trials. 2002-Fully accredited by the College of American Pathologists? Laboratory Accreditation Program. 2008-Awarded the CNBC TV18 Emerging India Award 2008 by ICICI Bank Business Banking in the pharmaceuticals and chemicals category. 2010-Franchisor of the Year in healthcare at the Franchise Plus Awards. -Honourable mention in the healthcare category at the Milagrow Trailblazers Brand Innovator Awards. 2012-Diagnostic Service Provider Company of the Year by Frost & Sullivan at the 4th Annual India Healthcare Excellence Awards. -Named a Computerworld Honours Laureate by the Computerworld Honours Program for innovative use of information technology to conduct research develop new diagnostic methods and services and improve quality and access of patients to healthcare. 2013-Best Diagnostic Company in India at the VC Circle Healthcare Summit. 2014-Received the ISO 27001:2013 certification for the information management system for providing data center services and supporting functions. -Received an NABL certificate of accreditation under standard ISO 15189:2012 for "Medical Laboratories ? Requirements for Quality and Competence" for medical testing for National Reference Laboratory. 2015-Data Quest Technology Award for Excellence in the implementation and use of technology for business benefits in the 'Cloud' category. -Received the certificate of affiliation from the Healthcare Sector Skill Council for role as medical laboratory technician in relation to institute at Gurgaon Haryana India. Major events and milestones :2005 & 2007-Investment by WestBridge I Investments Holdings. 2008-Acquisition of Paliwal Medicare Private Limited and Paliwal Diagnostics Private Limited. 2010 -Establishment of the National Reference Laboratory. 2010 & 2013-Investment pursuant to purchase of shares by Wagner Limited from WestBridge I Investment Holdings. 2013-Investment pursuant to purchase of shares by WestBridge Crossover Fund LLC from WestBridge I Investment Holdings. -Investment by SIH. 2014-Acquisition of APL Clinical Institute of Clinical Laboratory & Research Private Limited. 2015-Amalgamation of Sanya Chemicals Private Limited Amolak Diagnostics Private Limited Medex Healthcare Private Limited Medicave Diagnostic Centre Private Limited Medicave Medical Systems Private Limited and the Company.

Read More

Dr Lal Pathlabs. Management

NamePosition
Vinay GujralCompany Secretary & Compliance Officer
Arvind LalChairman
View More

Dr Lal Pathlabs. FAQs

Dr Lal Pathlabs. शेयर का खरीद मूल्य 1408.9 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Dr Lal Pathlabs. शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Dr Lal Pathlabs. शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 45.39 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Dr Lal Pathlabs. शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 9.36 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Dr Lal Pathlabs. शेयर का प्राइस-टू-बुक (पी/बी) रेशियो -16.17 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Dr Lal Pathlabs. का मार्केट कैप 23606.83 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Dr Lal Pathlabs. शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 1770.00 और 1272.60 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost